Improving the Decision to Pursue a Phase 3 Clinical Trial by Adjusting for Patient-Specific Factors in Evaluating Phase 2 Treatment Efficacy Data

Abstract

Phase 2 clinical trials are undertaken to provide evidence of treatment efficacy and safety. A test statistic that accounts for individual patient risk in the patient population is proposed and applied to a phase 2 clinical trial for castrate metastatic prostate cancer. The test statistic is computed to compare, for each patient, the observed 2-year survival outcome to the predicted 2-year survival probability. A logistic regression model, developed using historical data in the same patient population, is used to adjust for patient risk in predicting the 2-year survival probability. Goodness-of-fit procedures are performed to ensure that a proper model is fit to the data. The test result is compared to the score test, the binomial exact test, and Fisher's exact test, all of which use the average 2-year survival probability in the population as the parameter of interest. The results demonstrate the benefit of risk adjustment in determining treatment efficacy in a single-arm phase 2 trial. By adjusting for patient risk, this method can provide a more precise assessment of phase 2 treatment efficacy, thereby improving the decision whether to proceed to a phase 3 clinical trial.

Keywords

Key words: analysis of phase 2 clinical trial data heterogeneous patient population model-based test statistic. (Med Decis Making 2007;27:380—386)

Get full access to this article

View all access options for this article.

References

Simon RM , Steinberg SM , Hamilton M. , et al. Clinical trial designs for the early clinical development of therapeutic cancer vaccines. J Clin Oncol. 2001;19:1848—54.

Mazumdar M. , Fazzari M. , Panageas KS A standardization method to adjust for the effect of patient selection in phase II clinical trials. Stat Med. 2001;20:883—92.

Smaletz O. , Scher HI , Small EJ , et al. Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J Clin Oncol. 2002;20:3972—82.

Halabi S. , Small EJ , Kantoff PW , et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol. 2003;21:1232—7.

Cox DR Regression models and life tables (with discussion). J Royal Stat Soc (Series B). 1972;34:187—220.

Efron B. , Tibshirani RJ An Introduction to the Bootstrap. New York: Chapman & Hall; 1993.

Harrell FE Jr , Lee KL , Mark DB Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15:361—87.

Hosmer DW , Lemeshow S. Confidence interval estimates of an index of quality performance based on logistic regression models. Stat Med. 1995 ;14:2161—72.

Breslow N. Covariance analysis of censored survival data. Biometrics. 1974;30:89—99.

10.

Cox DR , McCullagh P. Some aspects of analysis of covariance. Biometrics. 1982;38:541—61.

11.

Health Insurance Portability and Accountability Act, Pub. L. No. 104-191 (August 21, 1996).

12.

Roberts WW , Bergstralh EJ , Blute ML , et al. Contemporary identification of patients at high risk of early prostate cancer recurrence after radical retropubic prostatectomy. Urology. 2001;57:1033—7.

13.

Simon R. , Wittes RE , Ellenberg SS Randomized phase II clinical trials. Cancer Treatment Rep. 1985;69:1375—81.

14.

Byar DP , Simon RM , Friedewald WT , et al. Randomized clinical trials: perspectives on some recent ideas . N Engl J Med. 1976;295:74—80.

15.

Schaid DJ , Wieand S. , Therneau TM Optimal two-stage screening designs for survival comparisons. Biometrika. 1990;77:507—13.

16.

Scher HI , Heller G. Picking the winners in a sea of plenty. Clin Cancer Res. 2002;8:400—4.